1. Dela Cruz SC, Tanoue TL, Matthay AR. Lung cancer: epidemiology, etiology and prevention. Clin Chest Med 2011; 32: 605-644.
2.
Cheng TD, Cramb MS, Baade DP, Youlden DR, Nwogu C, Reid ME. The international epidemiology of lung cancer: latest trends, disparities, and tumor characteristics. J Thorac Oncol 2016; 11: 1653-1671.
3.
Jung CY, Antonia SJ. Tumor immunology and immune checkpoint inhibitors in non-small cell lung cancer. Tuberc Resp Dis 2018; 81: 29-41.
4.
Roach C, Zhang N, Corigliano E, Jansson M, Toland G, Pon- to G, et al. Development of a companion diagnostic PD-L1 immunohistochemistry assay for pembrolizumab therapy in non-small-cell lung cancer. Appl Immunohistochem Mol Morphol 2016; 24: 392-397.
5.
Kerr KM, Tsao MS, Nicholson AG, Yatabe Y, Wistuba II, Hirsch FR, et al. Programmed death-ligand 1 immunohistochemistry in lung cancer: in what state is this art. J Thorac Oncol 2015; 10: 985-989.
6.
Yu H, Boyle AT, Zhou C, Rimm DL, Hirsch FR. PD-L1 expression in lung cancer. J Thorac Oncol 2017; 12: 157-159.
7.
Sakaguchi T, Iketani A, Ito K, Nishii Y, Katsuta K, Hataji O. Comparison of PD-L1 expression between preoperative biopsy specimens and surgical specimens in non-small cell lung cancer. Cancers (Basel) 2025; 17: 398.
8.
Shigeta N, Yokose T, Murakami S, Isaka T, Shinada K, Yoshio-ka E, et al. Mutation profile and programmed death ligand 1 status of patients with non-small cell lung cancer diagnosed with “adenocarcinoma” and “non-small cell carcinoma favor adenocarcinoma”. Thorac Cancer 2024; 15: 458-465.
9.
McLaughlin J, Han G, Schalper KA, Carvajal-Hausdorf D, Pelekanou V, Rehman J, et al. Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer. JAMA Oncol 2015; 2: 1-9.
10.
Gerdes MJ, Sevinsky CJ, Sood A, Adak S, Bello MO, Bordwell A, et al. Highly multiplexed single-cell analysis of formalin- fixed, paraffin-embedded cancer tissue. Proc Natl Acad Sci U S A 2013; 110: 11982-1197.
11.
Gompelmann D, Sinn K, Brugger J, Bernitzky D, Mosleh B, Prosch H, et al. Correlation of PD-L1 expression on tumour cells between diagnostic biopsies and surgical specimens of lung cancer in real life with respect to biopsy techniques and neoadjuvant treatment. J Cancer Res Clin Oncol 2023; 149: 1747-1754.
12.
Tsao MS, Kerr MK, Dacic S, Yatabe Y, Hirsch FR. IASLC atlas of PD-L1 immunohistochemistry testing in lung cancer. 1st ed. North Fort Myers: Editorial RX Press 2017.
13.
Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther 2015; 14: 847-856
14.
Hendry S, Byrne JD, Wright MG, Young RJ, Sturrock S, Cooper WA, et al. Comparison of four PD-L1 immunohisto chemical assays in lung cancer. J Thorac Oncol 2017; 12: 367-376.
15.
Thunnissen E, De Langen JA, Smit FE. PD-L1 IHC in NSCLC with a global and methodological perspective. Lung Cancer 2017; 113: 102-105.
16.
Katoda K, Nitadori JI, Woo MK, Sima CS, Finley DJ, Rusch VW, et al. Comprehensive pathological analyses in lung squamous cell carcinoma: single cell invasion, nuclear diameter and tumor budding are independent prognostic factors for worse outcomes. J Thorac Oncol 2014; 9: 1126-1139.
17.
Zhang M, Li G, Wang Y, Wang Y, Zhao S, Haihong P, et al. PD-L1 expression in lung cancer and its correlation with driver mutations: a meta-analysis. Sci Rep 2017; 7: 10255.
18.
Jin Y, Shen X, Pan Y, Zheng Q, Chen H, Hu H, et al. Correlation between PD-L1 expression and clinicopathological characteristics of non-small cell lung cancer: a real-world study of a large Chinese cohort. J Thorac Dis 2019; 11: 4591-4601.
19.
Huynh GT, Morales-Oyarvide V, Campo JM, Gainor JF, Bozkurtlar E, Uruga H, et al. Programmed cell death ligand 1 expression in resected lung adenocarcinomas: association with immune microenvironment. J Thorac Oncol 2016; 11: 1869-1878.
20.
Chang YC, Hsu PC, Li SH, Weng SH, KuoCH, Yang TY, et al. The prevalence of PD-L1 expression in lung cancer. Clin Oncol 2019; 4: 1591.
21.
Takada K, Okamoto T, Shoji F, Shimokawa M, Akamine T, Takamori S, et al. Clinical significance of PD-L1 protein expression in surgically resected primary lung adenocarcinoma. J Thorac Oncol 2016; 11: 1879-1890.
22.
Sun JM, Zhou W, Choi YL, Choi SJ, Kim SE, Wang Z, et al. Prognostic significance of PD-L1 in patients with non-small cell lung cancer: a large cohort study of surgically resected casses. J Thorac Oncol 2016; 11: 1003-1011.
23.
Rangachari D, Vanderlann AP, Shea M, Le X, Huberman MS, Kobayashi SS, et al. Correlation between classic driver oncogene mutations in EGFR, ALK or ROS1 and 22C3 PD-L1 ≥ 50% expression in lung adenocarcinoma. J Thorac Oncol 2017; 12: 878-883.
24.
Tang Y, Fang S, Zhang Y, Hong S, Kang S, Yan Y, et al. The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs. Oncotarget 2015; 6: 14209-14219
25.
Heymann JJ, Bulman WA, Swinarski D, Pagan CA, Crapanzano JP, Haghighi M, et al. PD-L1 expression in non-small cell lung carcinoma: comparison among cytology, small biopsy, and surgical resection specimens. Cancer Cytopathol 2017; 125: 896-907.
26.
Munari E, Zamboni G, Lunardi G, Marchionni L, Marconi M, Sommaggio M, et al. PD-L1 expression heterogeneity in non-small cell lung cancer: defining criteria for harmonization. J Thorac Oncol 2018; 13: 1113-1120.
27.
Pawelczyk K, Piotrowska A, Ciesielska U, Jablonska K, Gletzel- Plucinska N, Grzegrzolka J, et al. Role of PD-L1 expression in non-small cell lung cancer and their prognostic significance according to clinicopathological factors and diagnostic markers. Int J Mol Sci 2019; 20: 824.
28.
Uruga H, Bozkurtlar E, Huynh GT, Muzikansky A, Goto Y, Gomez-Caraballo M, et al. Programmed cell death ligand (PD-L1) expression in stage II and III lung adenocarcinomas and nodal metastases. J Thorac Oncol 2016; 12: 458-466.
29.
Wu S, Shi X, Sun J, Liu Y, Luo Y, Liang Z, et al. The significance of programmed cell death ligand 1 expression in resected lung adenocarcinoma. Oncotarget 2017; 8: 16421-1649.
30.
Driver RB, Miller AR, Miller T, Deavers M, Gorman B, Mody D, et al. Programmed death ligand-1 (PD-L1) expression in either tumor cells or tumor infiltrating immune cells correlates with solid and high-grade lung adenocarcinomas. Arch Pathol Lab Med 2017; 141: 1529-1532.
31.
Petrelli F, Maltese M, Tomasello G, Conti B, Borgonovo K, Cabiddu M, et al. Clinical and molecular predictors of PD-L1 expression in non-small cell lung cancer: a systematic review and meta-analysis. Clin Lung Cancer 2018; 19: 315-322.
32.
D’Incecco A, Andreozzi M, Ludovini V, Rossi E, Capodanno A, Landi L, et al. PD-1 and PD-L1 expression in molecularly selected non-small cell lung cancer patients. Br J Cancer 2015; 112: 95-102.
33.
Kitazono S, Fujiwara Y, Tsuta K, Utsumi H, Kanda S, Horinouchi H, et al. Reliability of small biopsy samples compared with resected specimens for the determination of programmed death-ligand 1 expression in non-small-cell lung cancer. Clin Lung Cancer 2015; 16: 385-390.
34.
Yang H, Shi J, Lin D, Li X, Zhao C, Wang Q, et al. Prognostic value of PD-L1 expression in combination with CD8+ TILs density in patients with surgically resected non-small cell lung cancer. Cancer Med 2018; 7: 32-45.
35.
Velcheti V, Schalper KA, Carvajal DE, Anagnostou VK, Syri-gos KN, Sznol M, et al. Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest 2014; 94: 107-116.
36.
Gainor FJ, Rizvi H, Jimenez Aguilar EJ, Skoulidis F, Yeap BY, Naidoo J, et al. Clinical activity of programmed cell death 1 (PD-L1) blockade in never, light and heavy smokers with non-small-cell lung cancer and PD-L1 expression. Ann Oncol 2020; 31: 404-411.
37.
Hirai A, Yoneda K, Shimajiri S, Kuroda K, Hanagiri T, Fujino Y, et al. Prognostic impact of programmed death-ligand 1 expression in correlation with human leukocyte antigen class I expression status in stage I adenocarcinoma of the lung. J Thorac Cardiovasc Surg 2018; 155: 382-392.
38.
Yvorel V, Patoir A, Casteillo F, Tissot C, Fournel P, Stachowicz ML, et al. PD-L1 expression in pleomorphic, spindle cell and giant cell carcinoma of the lung is related to TTF-1, p40 expression and might indicate a worse prognosis. PLoS One 2017; 12: e0180346.
39.
Ameratunga M, Asadi K, Lin X, Walkiewicz M, Murone C, Knight S, et al. PD-L1 and tumor infiltrating lymphocytes as prognostic markers in resected NSCLC. PloS One 2016; 11: e0153954.
40.
Wu Y, Ju Q, Qian B, Zhang F, Shi H. The effectiveness of PD-L1 inhibitors in non-small cell lung cancer (NSCLC) patients of different ages. Oncotarget 2018; 9: 7942-7948.
41.
Li H, Xu Y, Wan B, Song Y, Zhan P, Hu Y, et al. The clinicopathological and prognostic significance of PD-L1 expression assessed by immunohistochemistry in lung cancer: a meta- analysis of 50 studies with 11383 patients. Trasnl Lung Cancer Res 2019; 8: 429-449.
42.
Calles A, Liao X, Sholl L, Rodig SJ, Freeman GJ, Butaney M, et al. Expression of PD-L1 and its ligands, PD-L1 and PD-L2 in smokers and never smokers with KRAS mutant lung cancer. J Thorac Oncol 2015; 10: 1726-1735.
43.
Schmidt LH, Kummel A, Gorlich D, Mohr M, Bröckling S, Mikesch JH, et al. PD-1 and PD-L1 expression in NSCLC indicate a favorable prognosis in defined subgroups. PloS One 2015; 10: e0136023.
44.
Molina RJ, Yang P, Cassivi SD, Schild SE, Adjei AA, et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008; 83: 584-594.
45.
Kato Y, Kashima J, Watanabe K, Yomota M, Zenke Y, Oku-ma Y, et al. Association between clinicopathological features and programmed death ligand expression in non-small cell lung cancer. Anticancer Res 2018; 38: 1077-1083.
46.
Wang H, Agulnik A, Kasymjanova G, Wang A, Jiménez P, Cohen V, et al. Cytology cell blocks are suitable for immunohistochemical testing for PD-L1 in lung cancer. Ann Oncol 2018; 29: 1217-1222.
47.
Russell-Goldman E, Kravets S, Dahlberg ES, Sholl LM, Vive-ro M. Cytologic-histologic correlation of programmed death- ligand 1 immunohistochemistry in lung carcinomas. Cancer Cytopathol 2018; 126: 253-256.
48.
Gompelmann D, Sarova P, Mosleh B, Papaporfyriou A, Oberndorfer F, Idzko M, et al. PD-L1 assessment in lung cancer biopsies – pitfalls and limitations. Int J Biol Markers 2024; 39: 3-8.
49.
Mansour MSI, Malmros K, Mager U, Lindquist KE, Hejny K, Holmgren B, et al. PD-L1 expression in non-small cell lung cancer specimens: association with clinicopathological factors and molecular alterations. Int J Mol Sci 2022; 23: 4517.
50.
Ilie M, Long-Mira E, Bence C, Butori C, Lassalle S, Bouhlel L, et al. Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. Ann Oncol 2016; 27: 147-153.
